哈药集团人民同泰医药股份有限公司

Group 1 - The company held its 20th meeting of the 10th Board of Directors on June 4, 2025, with all 7 directors present, complying with legal and procedural requirements [2][3] - The Board approved the proposal to cancel the Supervisory Board and amend the Articles of Association, transferring the Supervisory Board's powers to the Audit Committee [3][6] - The Board also approved amendments to the Shareholders' Meeting Rules, changing "Shareholders' General Meeting" to "Shareholders' Meeting" [6][8] Group 2 - The company plans to hold the 2024 Annual Shareholders' Meeting on June 26, 2025, using a combination of on-site and online voting [30][48] - The voting will take place on the same day, with specific time slots for both on-site and online participants [49][50] - Shareholders must register to attend the meeting, with details provided for both in-person and remote registration [60][61] Group 3 - The company nominated candidates for the 11th Board of Directors, including Zhu Weidong, Yin Shiwei, and Gu Congfeng, pending shareholder approval [22][25] - Independent director candidates include Li Wen, Guo Dan, and Li Wenming, also subject to shareholder approval [25][36] - The company will purchase Directors and Officers liability insurance, with the proposal requiring shareholder approval due to the conflict of interest for all directors [28][43]